Evidence map›Paper›PMID 27748820›Full record

ArticleMolecular medicine reports2016

Label-free LC-MS/MS shotgun proteomics to investigate the anti-inflammatory effect of rCC16.

Min Pang, Xin-Yan Bai, Yan Li, Ji-Zhong Bai, Li-Rong Yuan, Shou-An Ren, Xiao-Yun Hu, Xin-Ri Zhang, Bao-Feng Yu, Rui Guo and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Min PangRespiratory Department, The First Affiliated Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Xin-Yan BaiDepartment of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Yan LiFan‑Xing Biological Technology Co., Ltd., Beijing 010000, P.R. China.
Ji-Zhong BaiDepartment of Physiology, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1142, New Zealand.
Li-Rong YuanRespiratory Department, The First Affiliated Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Shou-An RenRespiratory Department, The First Affiliated Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Xiao-Yun HuRespiratory Department, The First Affiliated Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Xin-Ri ZhangRespiratory Department, The First Affiliated Hospital, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Bao-Feng YuDepartment of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Rui GuoDepartment of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Hai-Long WangDepartment of Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China.
Shanxi Medical University · CNFirst Hospital of Shanxi Medical University · CNUniversity of Auckland · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clara cell protein (CC16) is an anti-inflammatory protein, which is expressed in the airway epithelium. It is involved in the development of airway inflammatory diseases, including chronic obstructive pulmonary disease and asthma. However, the exact molecular mechanism underlying its anti‑inflammatory action remains to be fully elucidated. The aim of the present study was to define the protein profiles of the anti‑inflammatory effect of CC16 in lipopolysaccharide (LPS)‑treated rat tracheal epithelial (RTE) cells using shotgun proteomics. Protein extracts were obtained from control RTE cells, RTE cells treated with LPS and RTE cells treated with LPS and recombinant CC16 (rCC16). Subsequent label‑free quantification and bioinformatics analyses identified 12 proteins that were differentially expressed in the three treatment groups as a cluster of five distinct groups according to their molecular functions. Five of the twelve proteins were revealed to be associated with the cytoskeleton: Matrix metalloproteinase‑9, myosin heavy chain 10, actin‑related protein‑3 homolog, elongation factor 1‑α‑1 (EF‑1‑α‑1), and acidic ribosomal phosphoprotein P0. Five of the twelve proteins were associated with cellular proliferation: DNA‑dependent protein kinase catalytic subunit, EF‑1‑α‑1, tyrosine 3‑monooxygenase, caspase recruitment domain (CARD) protein 12 and adenosylhomocysteinase (SAHH) 3. Three proteins were associated with gene regulation: EF‑1‑α‑1, SAHH 3 and acidic ribosomal phosphoprotein P0. Three proteins were associated with inflammation: Tyrosine 3‑monooxygenase, CARD protein 12 and statin‑related protein. ATPase (H+‑transporting, V1 subunit A, isoform 1) was revealed to be associated with energy metabolism, and uridine diphosphate glycosyltransferase 1 family polypeptide A8 with drug metabolism and detoxification. The identified proteins were further validated using reverse transcription‑quantitative polymerase chain reaction. These protein profiles, and their interacting protein network, may facilitate the elucidation of the molecular mechanisms underlying the anti‑inflammatory effects of CC16.

Indexed as

AnimalsChromatography, LiquidEpithelial CellsHumansInflammationLipopolysaccharidesProtein BiosynthesisProteomicsPulmonary Disease, Chronic ObstructiveRatsRecombinant ProteinsTandem Mass SpectrometryTracheaUteroglobinLipopolysaccharidesRecombinant ProteinsScgb1a1 protein, ratUteroglobin

Identifiers

PMID27748820
PMCPMC5101986
OpenAlexW2530420492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.